Use of recombinant alpha-2b-interferon in combination with antioxidants in the form of rectal suppositories (viferon) in children with chronic hepatitides B and C

[Guest guest]

1: Acta Virol 2000 Apr;44(2):79-83

Use of recombinant alpha-2b-interferon in combination with antioxidants in

the form of rectal suppositories (viferon) in children with chronic

hepatitides B and C.

Uchaikin V, Cherednichenko T, Malinovskaya V, Orlova T, Kovalev O,

Kharlamova F, Chaplygina G, Konev V, Voronina F, Delenian N.

Russian State Medical University, Moscow, Russia.

A new antiviral and immunomodulating preparation Viferon, produced as rectal

suppositories containing recombinant alpha-2b-interferon (IFN) and

antioxidants, was used in complex therapy of viral chronic hepatitides B and

C (ChHB and ChHC) in children. Results of our investigation showed a high

efficiency of Viferon. Viferon was found to suppress replication of

hepatotropic viruses and to decrease activity of the pathologic process in

the liver of children with ChHB and ChHC. After a Viferon treatment with

daily doses of (1-2) x 10(6) IU of IFN (3.0 x 10(6) IU/m2) primary remission

was registered in 78% of patients with ChHB and in 44% of patients with

ChHC, while lasting remission was found in 82% of ChHB and in 33% of ChHC

patients. Thus, a more marked effect was observed with ChHB, in which 3.0 x

10(6) IU/m2 was the optimal daily dose for children. Increasing the dose to

5.0 x 10(6) IU/m2 did not result in rise of the percentage of the

remissions. Side effects, which are characteristic for injection of IFN

preparations, were never found even after a longterm treatment. Absence of

induction of neutralizing antibodies was observed after administration of

alpha-2b-IFN, an integral part of Viferon. In pediatrics, the method of

rectal administration has advantages over parenteral delivery due to its

convenience, non-traumatic character and possibility of use for prolonged

periods.

PMID: 10989698 [PubMed - indexed for MEDLINE]

[Guest guest]

1: Acta Virol 2000 Apr;44(2):79-83

Use of recombinant alpha-2b-interferon in combination with antioxidants in

the form of rectal suppositories (viferon) in children with chronic

hepatitides B and C.

Uchaikin V, Cherednichenko T, Malinovskaya V, Orlova T, Kovalev O,

Kharlamova F, Chaplygina G, Konev V, Voronina F, Delenian N.

Russian State Medical University, Moscow, Russia.

A new antiviral and immunomodulating preparation Viferon, produced as rectal

suppositories containing recombinant alpha-2b-interferon (IFN) and

antioxidants, was used in complex therapy of viral chronic hepatitides B and

C (ChHB and ChHC) in children. Results of our investigation showed a high

efficiency of Viferon. Viferon was found to suppress replication of

hepatotropic viruses and to decrease activity of the pathologic process in

the liver of children with ChHB and ChHC. After a Viferon treatment with

daily doses of (1-2) x 10(6) IU of IFN (3.0 x 10(6) IU/m2) primary remission

was registered in 78% of patients with ChHB and in 44% of patients with

ChHC, while lasting remission was found in 82% of ChHB and in 33% of ChHC

patients. Thus, a more marked effect was observed with ChHB, in which 3.0 x

10(6) IU/m2 was the optimal daily dose for children. Increasing the dose to

5.0 x 10(6) IU/m2 did not result in rise of the percentage of the

remissions. Side effects, which are characteristic for injection of IFN

preparations, were never found even after a longterm treatment. Absence of

induction of neutralizing antibodies was observed after administration of

alpha-2b-IFN, an integral part of Viferon. In pediatrics, the method of

rectal administration has advantages over parenteral delivery due to its

convenience, non-traumatic character and possibility of use for prolonged

periods.

PMID: 10989698 [PubMed - indexed for MEDLINE]

[Guest guest]

1: Acta Virol 2000 Apr;44(2):79-83

Use of recombinant alpha-2b-interferon in combination with antioxidants in

the form of rectal suppositories (viferon) in children with chronic

hepatitides B and C.

Uchaikin V, Cherednichenko T, Malinovskaya V, Orlova T, Kovalev O,

Kharlamova F, Chaplygina G, Konev V, Voronina F, Delenian N.

Russian State Medical University, Moscow, Russia.

A new antiviral and immunomodulating preparation Viferon, produced as rectal

suppositories containing recombinant alpha-2b-interferon (IFN) and

antioxidants, was used in complex therapy of viral chronic hepatitides B and

C (ChHB and ChHC) in children. Results of our investigation showed a high

efficiency of Viferon. Viferon was found to suppress replication of

hepatotropic viruses and to decrease activity of the pathologic process in

the liver of children with ChHB and ChHC. After a Viferon treatment with

daily doses of (1-2) x 10(6) IU of IFN (3.0 x 10(6) IU/m2) primary remission

was registered in 78% of patients with ChHB and in 44% of patients with

ChHC, while lasting remission was found in 82% of ChHB and in 33% of ChHC

patients. Thus, a more marked effect was observed with ChHB, in which 3.0 x

10(6) IU/m2 was the optimal daily dose for children. Increasing the dose to

5.0 x 10(6) IU/m2 did not result in rise of the percentage of the

remissions. Side effects, which are characteristic for injection of IFN

preparations, were never found even after a longterm treatment. Absence of

induction of neutralizing antibodies was observed after administration of

alpha-2b-IFN, an integral part of Viferon. In pediatrics, the method of

rectal administration has advantages over parenteral delivery due to its

convenience, non-traumatic character and possibility of use for prolonged

periods.

PMID: 10989698 [PubMed - indexed for MEDLINE]

[Guest guest]

1: Acta Virol 2000 Apr;44(2):79-83

Use of recombinant alpha-2b-interferon in combination with antioxidants in

the form of rectal suppositories (viferon) in children with chronic

hepatitides B and C.

Uchaikin V, Cherednichenko T, Malinovskaya V, Orlova T, Kovalev O,

Kharlamova F, Chaplygina G, Konev V, Voronina F, Delenian N.

Russian State Medical University, Moscow, Russia.

A new antiviral and immunomodulating preparation Viferon, produced as rectal

suppositories containing recombinant alpha-2b-interferon (IFN) and

antioxidants, was used in complex therapy of viral chronic hepatitides B and

C (ChHB and ChHC) in children. Results of our investigation showed a high

efficiency of Viferon. Viferon was found to suppress replication of

hepatotropic viruses and to decrease activity of the pathologic process in

the liver of children with ChHB and ChHC. After a Viferon treatment with

daily doses of (1-2) x 10(6) IU of IFN (3.0 x 10(6) IU/m2) primary remission

was registered in 78% of patients with ChHB and in 44% of patients with

ChHC, while lasting remission was found in 82% of ChHB and in 33% of ChHC

patients. Thus, a more marked effect was observed with ChHB, in which 3.0 x

10(6) IU/m2 was the optimal daily dose for children. Increasing the dose to

5.0 x 10(6) IU/m2 did not result in rise of the percentage of the

remissions. Side effects, which are characteristic for injection of IFN

preparations, were never found even after a longterm treatment. Absence of

induction of neutralizing antibodies was observed after administration of

alpha-2b-IFN, an integral part of Viferon. In pediatrics, the method of

rectal administration has advantages over parenteral delivery due to its

convenience, non-traumatic character and possibility of use for prolonged

periods.

PMID: 10989698 [PubMed - indexed for MEDLINE]